Back to Search
Start Over
ESMO: AstraZeneca steps out from Daiichi's shadow, posting data on ADC rivals to AbbVie, Pfizer.
- Source :
- FierceBiotech; 9/14/2024, pN.PAG-N.PAG, 1p
- Publication Year :
- 2024
-
Abstract
- AstraZeneca has shared an early look at its in-house ADCs, publishing phase 1 data on assets that could compete with molecules from AbbVie and Pfizer. [ABSTRACT FROM AUTHOR]
- Subjects :
- ANTIBODY-drug conjugates
CLINICAL trials
ASSETS (Accounting)
MOLECULES
TUMORS
Subjects
Details
- Language :
- English
- Database :
- Complementary Index
- Journal :
- FierceBiotech
- Publication Type :
- Periodical
- Accession number :
- 179649487